Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipatasertib PK in Hepatic Impairment
NCT03341884Phase 1Completed
- Sponsor
- Genentech
- Start
- Nov 2017
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ipatasertib in prostate cancer (PCa), breast cancer and solid tumor (4 arms), sponsored by Genentech. Primary endpoints: Area Under the Plasma Concentration-Time Curve from 0 to Infinity and Maximum Observed Plasma Concentration. Started Nov 2017; status: completed.
02
Drugs
ipatasertib
03
Conditions
prostate cancer (PCa)breast cancersolid tumor
Beyond the preview
Go deeper on NCT03341884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03341884.